A Clinical Overview of Peptide Therapy: What Providers Need to Know About the Most-Requested Categories

More patients are walking in with peptide questions. Here's a clear, honest overview of the three categories getting the most attention — and what actually matters when you're deciding whether to prescribe.

Peptides are having a moment. Patients are researching them on their own, showing up to appointments with specific names, and sometimes arriving with protocols they found online. Monthly searches for CJC-1295/ipamorelin alone have more than doubled in the last year — from roughly 27,000 to over 60,000 per month in 2026.

The good news: most of the interest is clustering around a handful of well-characterized categories. The honest reality: this space is still mostly off-label, still compounding-dependent, and the clinical trial data doesn't always match the enthusiasm.

This guide covers the three categories your patients are most likely to ask about. For each one, we'll walk through how it works, what the evidence actually looks like, who tends to benefit, and what to watch out for.

Growth Hormone Secretagogues: CJC-1295, Ipamorelin, and Sermorelin

The Basic Idea

These aren't growth hormone. They're peptides that prompt the pituitary to release its own GH — which means the body's natural feedback loops stay intact. That's an important distinction, both for safety and for how you explain it to patients.

Sermorelin was the default for two decades. It mimics GHRH and works well, but it clears the system in about 10–20 minutes. The GH pulse is brief. Some patients also see mild cortisol and prolactin bumps, which isn't ideal.

CJC-1295 is essentially a longer-acting version of the same idea. A structural modification lets it bind to albumin in circulation, extending its half-life to 6–8 days. The result is a more sustained GH signal without daily injection burden.

Ipamorelin works through a different receptor entirely (GHS-R1a, the ghrelin receptor), which makes it a natural stack partner with CJC-1295 rather than a replacement. Its main advantage is selectivity — it produces a clean GH pulse without meaningfully affecting cortisol, prolactin, or appetite hormones. That's why most clinics have moved away from sermorelin monotherapy and toward the CJC-1295/ipamorelin combination.

What the Evidence Shows

The mechanism is well-understood and biologically sound. Clinical use is off-label, and most of the data comes from open-label trials, real-world clinic experience, and patient-reported outcomes — which is typical for this stage of functional medicine research. Providers have been using these protocols for years with a strong track record in the right patient populations.

Who Tends to Benefit

Look for adults with a consistent cluster: fatigue, poor sleep quality, slow recovery, body composition shifts, and low-normal or confirmed low IGF-1. Before starting:

• Pull a baseline IGF-1, fasting glucose, insulin, and a basic metabolic panel

• Screen for sleep apnea (GH elevation can worsen it)

• Active malignancy is a contraindication

• Patients with insulin resistance or diabetes need closer monitoring — GH can be mildly insulin-antagonizing

• Anyone with a pituitary adenoma history warrants extra caution
  

Typical protocols are subcutaneous, dosed at night to align with the body's natural GH rhythm, cycled every 3–6 months to preserve receptor sensitivity.

Tissue Repair Peptides: BPC-157 and TB-500

The Basic Idea

BPC-157 is a short peptide derived from a gastric protein. It's been called a "systemic repair signal" — it promotes new blood vessel formation, stimulates fibroblast activity in tendons and ligaments, supports nitric oxide pathways in injured tissue, and has well-documented cytoprotective effects on the GI tract. Patients with slow-healing musculoskeletal injuries or gut complaints are where you'll see the most interest.

TB-500 is a synthetic fragment of thymosin beta-4. It works differently — its strength is promoting cell migration and vascular remodeling, which creates a better environment for tissue regeneration. Providers often pair it with BPC-157 on the logic that their mechanisms are complementary: BPC-157 does the structural repair work, TB-500 supports the regenerative scaffolding around it.

What the Evidence Shows

The foundation here is a deep body of preclinical research — decades of animal studies across musculoskeletal injuries, gut healing, and neurological repair that consistently point in the same direction. BPC-157 in particular has been one of the more studied peptides in this category, with published research and growing interest from integrative providers who have used it for years with a favorable safety profile and strong patient-reported outcomes.

Human clinical trials are still catching up to the preclinical evidence — which is true of many emerging therapies in functional and integrative medicine. As the field matures, expect the human data to follow. For now, providers using these peptides are working in a space that is evidence-informed, if not yet evidence-complete.

Where Providers Are Using Them

• Tendinopathy, ligament injuries, and post-surgical musculoskeletal recovery

• GI complaints — particularly leaky gut presentations, IBD-adjacent cases, and NSAID-related GI irritation

• Recovery optimization in active patients whose injuries aren't progressing on standard care

• Post-surgical healing protocols, often as a BPC-157/TB-500 combination
  

Route of administration is flexible — subcutaneous injection is most common, but oral, sublingual, and intranasal formulations are available through compounding depending on the target tissue.

Immune-Modulating Peptides: Thymosin Alpha-1 and Thymosin Beta-4

The Basic Idea

Thymosin Alpha-1 (Tα1) is a naturally occurring peptide produced by the thymus. Think of it as a volume knob for immune function — it promotes T-cell differentiation and activation, enhances NK cell activity, and modulates the signaling pathways that coordinate both the innate and adaptive immune response. It doesn't hammer the immune system; it helps it calibrate.

Thymosin Beta-4 (the full protein, distinct from TB-500 which is just a fragment) overlaps somewhat — it also reduces local inflammation — but its primary role is tissue repair and angiogenesis rather than immune regulation.

What the Evidence Shows

Thymosin Alpha-1 has the most substantial clinical evidence base of anything in this guide. It's approved in over 35 countries for hepatitis B and C, where it improves viral clearance when combined with antivirals. It's been studied as an adjuvant in oncology — hepatocellular carcinoma, NSCLC, and melanoma — alongside chemotherapy. A 2025 review documented its effects on immunosenescence, including improved vaccine response in older patients and enhanced thymic output — findings that are increasingly relevant as longevity medicine grows.

Where providers are using it:

• Post-illness immune recovery, particularly in patients with prolonged immune suppression after infection

• Chronic viral conditions and hepatitis management

• Vaccine response optimization in older or immunocompromised patients

• Oncology support (in coordination with the patient's oncology team)
  

A Practical Framework Before You Prescribe

Across all three categories, a consistent workup makes the process cleaner:

• Baseline labs: IGF-1 (GH peptides), CBC with differential, CMP, thyroid panel, sex hormones as appropriate. For Tα1, consider an immune panel.

• Contraindications: Active malignancy for GH secretagogues; uncontrolled autoimmune conditions; pregnancy or breastfeeding.

• Informed consent: Off-label status, current evidence level, administration route, likely side effects (injection site reactions, mild water retention with GH peptides, transient fatigue with Tα1), and your monitoring plan.

• Follow-up: IGF-1 at 3 months for GH peptide protocols; patient-reported outcomes documented consistently.
  

How We Can Help Navigating peptide therapy — the sourcing questions, the regulatory shifts, the patient conversations — can feel like a moving target. We stay current on the landscape so you don't have to do it alone.

At Good Day Pharmacy, we're a local, independent pharmacy that follows this space closely. If you have questions about what's available, what's changing, or how to talk through options with your patients, we're a good first call.

We're real people who answer the phone. Reach out anytime.